|
Gene: RPL7 |
Gene summary for RPL7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL7 | Gene ID | 6129 |
Gene name | ribosomal protein L7 | |
Gene Alias | L7 | |
Cytomap | 8q21.11 | |
Gene Type | protein-coding | GO ID | GO:0000463 | UniProtAcc | P18124 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6129 | RPL7 | GSM4909285 | Human | Breast | IDC | 9.13e-07 | 1.53e-01 | 0.21 |
6129 | RPL7 | GSM4909286 | Human | Breast | IDC | 1.02e-51 | 2.83e-01 | 0.1081 |
6129 | RPL7 | GSM4909287 | Human | Breast | IDC | 1.01e-15 | -2.70e-01 | 0.2057 |
6129 | RPL7 | GSM4909290 | Human | Breast | IDC | 5.23e-19 | -2.37e-01 | 0.2096 |
6129 | RPL7 | GSM4909291 | Human | Breast | IDC | 2.47e-25 | 2.58e-01 | 0.1753 |
6129 | RPL7 | GSM4909293 | Human | Breast | IDC | 5.95e-41 | -2.27e-01 | 0.1581 |
6129 | RPL7 | GSM4909296 | Human | Breast | IDC | 3.40e-06 | 1.26e-01 | 0.1524 |
6129 | RPL7 | GSM4909298 | Human | Breast | IDC | 2.18e-11 | -1.08e-01 | 0.1551 |
6129 | RPL7 | GSM4909301 | Human | Breast | IDC | 2.47e-29 | -2.61e-01 | 0.1577 |
6129 | RPL7 | GSM4909302 | Human | Breast | IDC | 5.78e-03 | -1.53e-01 | 0.1545 |
6129 | RPL7 | GSM4909303 | Human | Breast | IDC | 3.38e-12 | -4.09e-01 | 0.0438 |
6129 | RPL7 | GSM4909304 | Human | Breast | IDC | 2.72e-67 | -3.92e-01 | 0.1636 |
6129 | RPL7 | GSM4909305 | Human | Breast | IDC | 3.00e-15 | 1.83e-01 | 0.0436 |
6129 | RPL7 | GSM4909306 | Human | Breast | IDC | 4.86e-12 | 1.65e-01 | 0.1564 |
6129 | RPL7 | GSM4909311 | Human | Breast | IDC | 6.77e-09 | 7.65e-02 | 0.1534 |
6129 | RPL7 | GSM4909312 | Human | Breast | IDC | 5.82e-46 | 2.81e-01 | 0.1552 |
6129 | RPL7 | GSM4909313 | Human | Breast | IDC | 1.30e-03 | -1.67e-01 | 0.0391 |
6129 | RPL7 | GSM4909315 | Human | Breast | IDC | 9.93e-45 | -4.46e-01 | 0.21 |
6129 | RPL7 | GSM4909316 | Human | Breast | IDC | 1.44e-27 | -7.29e-01 | 0.21 |
6129 | RPL7 | GSM4909317 | Human | Breast | IDC | 3.49e-26 | -2.77e-01 | 0.1355 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00004707 | Esophagus | HGIN | maturation of LSU-rRNA | 10/2587 | 28/18723 | 3.04e-03 | 2.88e-02 | 10 |
GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:0042273111 | Esophagus | ESCC | ribosomal large subunit biogenesis | 65/8552 | 72/18723 | 1.53e-15 | 9.82e-14 | 65 |
GO:000047016 | Esophagus | ESCC | maturation of LSU-rRNA | 27/8552 | 28/18723 | 9.94e-09 | 2.00e-07 | 27 |
GO:000182412 | Esophagus | ESCC | blastocyst development | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
GO:00004634 | Esophagus | ESCC | maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 15/8552 | 15/18723 | 7.81e-06 | 7.69e-05 | 15 |
GO:00018253 | Esophagus | ESCC | blastocyst formation | 29/8552 | 38/18723 | 1.18e-04 | 8.13e-04 | 29 |
GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
GO:00226137 | Liver | NAFLD | ribonucleoprotein complex biogenesis | 76/1882 | 463/18723 | 1.19e-05 | 3.67e-04 | 76 |
GO:00422737 | Liver | NAFLD | ribosomal large subunit biogenesis | 20/1882 | 72/18723 | 1.83e-05 | 5.29e-04 | 20 |
GO:00422547 | Liver | NAFLD | ribosome biogenesis | 52/1882 | 299/18723 | 6.03e-05 | 1.32e-03 | 52 |
GO:00344704 | Liver | NAFLD | ncRNA processing | 57/1882 | 395/18723 | 3.34e-03 | 2.93e-02 | 57 |
GO:00063644 | Liver | NAFLD | rRNA processing | 35/1882 | 225/18723 | 6.04e-03 | 4.54e-02 | 35 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL7 | SNV | Missense_Mutation | novel | c.11N>G | p.Val4Gly | p.V4G | P18124 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL7 | insertion | Frame_Shift_Ins | novel | c.273_274insCCATTTAGGGCAAAGCTTATGTGCATTCAGCAGCTTAGAG | p.Val92ProfsTer53 | p.V92Pfs*53 | P18124 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RPL7 | SNV | Missense_Mutation | novel | c.133N>A | p.Ala45Thr | p.A45T | P18124 | protein_coding | tolerated(0.13) | benign(0.082) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RPL7 | SNV | Missense_Mutation | novel | c.668N>G | p.Lys223Arg | p.K223R | P18124 | protein_coding | deleterious(0.02) | benign(0.157) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
RPL7 | SNV | Missense_Mutation | c.469N>T | p.Arg157Cys | p.R157C | P18124 | protein_coding | tolerated(0.09) | benign(0.068) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
RPL7 | SNV | Missense_Mutation | c.65N>A | p.Arg22Gln | p.R22Q | P18124 | protein_coding | tolerated(0.26) | benign(0.202) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
RPL7 | SNV | Missense_Mutation | novel | c.118N>C | p.Lys40Gln | p.K40Q | P18124 | protein_coding | tolerated(0.06) | possibly_damaging(0.457) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RPL7 | SNV | Missense_Mutation | novel | c.269C>T | p.Ala90Val | p.A90V | P18124 | protein_coding | tolerated(0.16) | benign(0.044) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL7 | SNV | Missense_Mutation | c.128N>A | p.Arg43Gln | p.R43Q | P18124 | protein_coding | tolerated(0.39) | benign(0.025) | TCGA-AG-3742-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL7 | SNV | Missense_Mutation | novel | c.698C>T | p.Ala233Val | p.A233V | P18124 | protein_coding | tolerated(0.24) | benign(0.178) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |